Malamou-Mitsi Vassiliki, Crikoni Olga, Timotheadou Eleni, Aravantinos Gerassimos, Vrettou Eleni, Agnantis Niki, Fountzilas George
Department of Pathology, University of Ioannina School of Medicine, Ioannina, Greece.
Anticancer Res. 2007 Mar-Apr;27(2):1157-65.
Several oncogenes and onco-suppressor genes have been implicated in epithelial ovarian carcinogenesis, but their clinical significance is not clear and conflicting data have been found in various studies.
The immunohistochemical expression of HER-2, p53 and Bcl-2 proteins was investigated in a cohort of 95 patients with advanced epithelial ovarian cancer (stages IIc-IV). These patients participated in a phase III randomized clinical trial and were treated either with paclitaxel/carboplatin, orpaclitaxel/carboplatin alternating with paclitaxel/cisplatin.
Positive immunostaining for HER-2, p53 and Bcl-2 proteins was found in 18%, 70.5% and 69.5% of the cases, respectively. In multivariate analysis, older patients (< 63 vs. > or = 63 years, p < 0.001), worse grade (I-II vs. III, p = 0.04) and p53 expression (negative vs. positive, p = 0.002) were significant prognostic factors independently associated with survival.
p53 status along with age and grade appear to be independent prognostic factors for survival in patients with epithelial ovarian cancer.
多种癌基因和抑癌基因与上皮性卵巢癌的发生有关，但其临床意义尚不清楚，且在各项研究中发现了相互矛盾的数据。
对95例晚期上皮性卵巢癌（IIc - IV期）患者进行了HER - 2、p53和Bcl - 2蛋白的免疫组化表达研究。这些患者参与了一项III期随机临床试验，接受紫杉醇/卡铂治疗，或紫杉醇/卡铂与紫杉醇/顺铂交替治疗。
HER - 2、p53和Bcl - 2蛋白免疫染色阳性分别见于18%、70.5%和69.5%的病例。多因素分析显示，年龄较大（< 63岁与≥63岁，p < 0.001）、分级较差（I - II级与III级，p = 0.04）以及p53表达（阴性与阳性，p = 0.002）是与生存独立相关的显著预后因素。
p53状态以及年龄和分级似乎是上皮性卵巢癌患者生存的独立预后因素。
Zotero 插件